After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...
The price to buy certain infused biosimilars can be three times higher than reimbursement, and the problem is growing.
Biosimilar Pipeline Analysis Market BURLINGAME, CA, UNITED STATES, February 6, 2025 /EINPresswire / -- The global Biosimilar Pip ...
The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...
Biologic treatments have revolutionised medicine and, following in their footsteps, biosimilars are set to continue the progression in healthcare. With the reduced cost of biosimilars comes ...
After years of patent protection, biosimilars for Humira are set to enter the US market in 2023. The arrival of these drugs has been widely anticipated throughout the healthcare industry.
Dr. Reddy's (RDY) partners with Shanghai Henlius Biotech to develop and market biosimilar versions of J&J's (JNJ) multiple ...
The two products, both manufactured by Amgen, are aflibercept biosimilars Pavblu and Skojoy. Both biosimilars are indicated ...
The new biosimilar, Celltrion’s Avtozma, was approved in both IV and subcutaneous forms to treat inflammatory conditions such as arthritis.
Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback